Navigation Links
Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
Date:3/5/2013

RICHMOND, Calif., March 5, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier , Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 4:45 pm ET on Wednesday, March 13, 2013, at the Barclays Global Healthcare Conference which will be held in Miami.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

 


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
5. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
8. Neurocrine Biosciences Reports First Quarter 2012 Results
9. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
10. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
11. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2020)... ... January 03, 2020 , ... In Partnership with the Smiles ... low-income, underinsured individuals at its Burleson, TX office on February 8th. , Dental services ... cleanings and extractions . For more information, please visit the ...
(Date:1/2/2020)... ... ... In an age of the current mental health crisis, it’s a lesson ... embrace acceptance and understanding of the needs of atypical’s that are one of the ... a new story that represents the Children’s First Mental Health Primer. Come aboard to ...
(Date:12/31/2019)... (PRWEB) , ... December 31, 2019 , ... ... on addressing unmet needs in the field of urology, today announced that Dr. ... designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Daily ...
Breaking Medicine Technology:
(Date:1/12/2020)... ... January 12, 2020 , ... ... in New York City, has continually innovated for over a decade to transform ... and medical device companies and self-insured employers. By optimizing the mix of expert ...
(Date:1/10/2020)... (PRWEB) , ... January 10, 2020 , ... ... the complexities of autoimmune conditions, HMP, a leading healthcare event and education company, ... help improve patient care. , The Autoimmune Learning Network serves as a robust ...
(Date:1/8/2020)... ... January 08, 2020 , ... Pyxa Solutions, a ... today that the company is rebranding as Red Nucleus R&D, a division of ... for the life sciences industry. , The addition of Red Nucleus R&D ...
(Date:1/7/2020)... ... January 07, 2020 , ... ... develops tools for characterizing microbiome populations down to the strain level, has ... Japanese biotech organization. , TOMY provides high-quality instruments and services to industry ...
(Date:1/7/2020)... ... , ... CBD For The People was created with the belief ... individual customer service experience. Transparency and integrity are the core of this company. CBD ... care of the people first, they know that satisfied customers will bring back more ...
Breaking Medicine News(10 mins):